Use your antibodies-online credentials, if available.
No Products on your Comparison List.
Your basket is empty.
Find out more
Show all species
Show all synonyms
Select your species
Results indicate that MAPK (show MAPK1 ELISA Kits) pathway inhibition leads to changes in the immunological properties of mutant BRAF melanoma cells.
Results show that promoter mutations render telomerase reverse transcriptase (TERT (show TERT ELISA Kits)) expression dependent on MAPK (show MAPK1 ELISA Kits) signal pathway activation due to oncogenic BRAF or NRAS (show NRAS ELISA Kits) mutations.
Of these 6 patients, 3 had a BRAF mutation positive primary with a BRAF mutation negative metastatic lesion, while the other 3 had a BRAF mutation negative primary with BRAF mutation positive metastasis.There is an important discordance rate in the BRAF mutation status of melanoma primaries versus brain metastases.
The BRAF V600 mutations were significantly associated with AQP1 expression (P=0.014). Long-term follow-up indicated a reduced progression-free survival (P=0.036) and overall survival (P=0.017) for the AQP1-positive cutaneous melanoma patients.
This study demonstrates that idiopathic pulmonary fibrosis-associated lung cancer (IPF-LC) is genetically characterized by the presence of somatic mutations reflecting a variety of environmental exposures on the background of specific germline mutations, and is associated with potentially targetable alterations such as BRAF mutations.
Study found that BRAF alterations are frequent in dysembryoplastic neuroepithelial tumors (DNTs), particularly BRAF copy number gain which is being reported for the first time in these tumors. Evidence of activation of mTOR (show FRAP1 ELISA Kits) and MAPK (show MAPK1 ELISA Kits) pathways suggests a role for altered signalling in DNT (show NT5C ELISA Kits) pathogenesis.
Mutations in KRAS and BRAF were associated with inferior PFS and OS of mCRC patients compared with patients with non-mutated tumors. KRAS exon 2 mutation variants were associated with heterogeneous outcome compared with unmutated tumors with KRAS G12C and G13D (trend) being associated with rather poor survival
The BRAF/MAP2K1-mut LCH cells had a more immature state than BRAF/MAP2K1-wt LCH cells. Authors also found the BRAFV600E and MAP2K1 mutations were significantly associated with pERK expression.
Association of the Bethesda category with BRAF mutation can slightly improve the value of stage prediction in papillary thyroid cancer.
The results demonstrated the lack of activity of anti-EGFRs in RAS(KRAS and NRAS (show NRAS ELISA Kits)) and BRAF wild-type, right-sided tumors, thus suggesting a potential role for primary tumor location in driving treatment choices
BRAF alternative splicing is differentially regulated in vertebrates. Exon 9b is present in all vertebrates, including Xenopus, but exon 8b is present only in eutherians.
Gene expression studies nominated TWIST2 (show TWIST2 ELISA Kits) as a key effector downstream of BRAF.
BRAF alternative splicing is differentially regulated in vertebrates. Exon 9b is present in all vertebrates, including Danio rerio, but exon 8b is present only in eutherians.
BRAF activation is sufficient for f-nevus formation, and is among the primary events in melanoma development.
BRAF alternative splicing is differentially regulated in rodent and primates. Exon 9b is present in vertebrates but exon 8b is present only in eutherians.
expression of an endogenous Braf(D631A) kinase-inactive isoform in mice (corresponding to the human BRAF(D594A) mutation) triggers lung adenocarcinoma in vivo, indicating that BRAF-inactivating mutations are initiating events in lung oncogenesis
TTM (show SLITRK1 ELISA Kits) reduces copper levels and MAPK (show MAPK1 ELISA Kits) signaling, thereby inhibiting BRAF(V600E)-driven melanoma tumor growth.
BRAF and ROKalpha (show ROCK2 ELISA Kits) form independent RAF1 (show RAF1 ELISA Kits) complexes in embryonic fibroblasts (MEFs) treated with epidermal growth factor (EGF (show EGF ELISA Kits)).
Braf(V600E) expression, coupled with simultaneous p53 (show TP53 ELISA Kits) ablation, permits bypass of senescence and progression to lung adenocarcinoma.
These results provide support for the role of BRAF(V600E) in metastasis.
Mechanistically, BRAF and RAF1 (show RAF1 ELISA Kits) operate independently to balance MAPK (show MAPK1 ELISA Kits) signaling: BRAF promotes ERK (show EPHB2 ELISA Kits) activation, while RAF1 (show RAF1 ELISA Kits) dims stress kinase activation.
Mass spectrometry based screening for potential interaction partners revealed that BRAF interacts and phosphorylates PAX3 (show PAX3 ELISA Kits).
Using a conditional allele for Braf(V600E) , a mutation observed in clinical cases of GIST, authors observed that Braf(V600E) activation was sufficient to drive ICC hyperplasia but not GIST tumorigenesis.
This study detected the BrafV637E mutation by whole-exome analysis in 4/4 hepatic tumors induced by neonatal treatment with diethylnitrosamine (DEN) in male B6C3F1 mice.
a critical threshold for inhibition of MAPK (show MAPK1 ELISA Kits) signaling is required to optimally restore expression of thyroid differentiation genes in thyroid cells and in mice with BrafV600E-induced thyroid cancer.
This gene encodes a protein belonging to the raf/mil family of serine/threonine protein kinases. This protein plays a role in regulating the MAP kinase/ERKs signaling pathway, which affects cell division, differentiation, and secretion. Mutations in this gene are associated with cardiofaciocutaneous syndrome, a disease characterized by heart defects, mental retardation and a distinctive facial appearance. Mutations in this gene have also been associated with various cancers, including non-Hodgkin lymphoma, colorectal cancer, malignant melanoma, thyroid carcinoma, non-small cell lung carcinoma, and adenocarcinoma of lung. A pseudogene, which is located on chromosome X, has been identified for this gene.
94 kDa B-raf protein
, B-Raf proto-oncogene serine/threonine-protein kinase (p94)
, murine sarcoma viral (v-raf) oncogene homolog B1
, proto-oncogene B-Raf
, serine/threonine-protein kinase B-raf
, v-raf murine sarcoma viral oncogene homolog B1
, B-Raf proto-oncogene serine/threonine-protein kinase
, proto-oncogene c-Rmil
, rmil serine/threonine-protein kinase
, serine/threonine kinase
, serine/threonine-protein kinase Rmil
, serine/threonine protein kinase BRAF
, serine/threonine-protein kinase B-raf-like
, B-raf protein
, uncharacterized protein LOC561722